公开(公告)号：US20160016907A1

公开(公告)日：2016-01-21

申请号：US14799621

申请日：2015-07-15

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  JENNIFER ELIZABETH DAVOREN ,  MICHELLE RENEE GARNSEY ,  LEI ZHANG ,  STEVEN VICTOR O'NEIL

IPC: C07D213/81 ,  C07D417/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D213/81 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides, in part, compounds of Formula I: N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M1-mediated (or M1-associated) disorders including, e.g., Alzheimer's disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Abstract translation: 本发明部分提供式I的化合物：其N-氧化物和化合物或N-氧化物的药学上可接受的盐; 制备过程; 中间体用于制备; 以及含有这些化合物，N-氧化物或盐的组合物及其用于治疗M1介导的（或M1相关）疾病的用途，包括例如阿尔茨海默病，精神分裂症（例如其认知和阴性症状），疼痛，成瘾， 和睡眠障碍。